Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q3 2024

Cerevel Therapeutics reports successful 2022, eyes transformative neuroscience advancements

Cerevel Therapeutics had a productive year, focusing on transformative neuroscience.
Strong financial position with cash resources to fund operations into 2025.
Facing challenges with trial delays but addressing them with mitigation plans.
Opportunities lie in upcoming data readouts and exploring new indications.

Cerevel Therapeutics reports strong financials, navigates trial challenges for growth

Cerevel Therapeutics is well-positioned financially with a focus on operational efficiency and trial success, supported by strong cash reserves.
The company faces challenges in pipeline management and trial enrollment dynamics, necessitating strategic adjustments and careful oversight.
Opportunities lie in external growth initiatives, potential product approvals, and expanding therapeutic reach through strategic trial designs.

Cerevel Therapeutics advances key programs amidst challenges, eyes growth opportunities

Cerevel Therapeutics is making progress in key programs, leveraging its strong balance sheet and commitment to patients. Challenges in trial delays and patient selection criteria persist, but the company's focus on quality data and financial strength bode well for future growth.

Cerevel Therapeutics excels in Q3 with robust pipeline and financials

Cerevel Therapeutics demonstrated robust performance in Q3 2023, driven by a strong pipeline and solid financial foundation.
While facing challenges like high rollover rates and data disclosure timelines, the company is well-positioned to capitalize on transformative opportunities.
Strategic focus on quality, innovation, and market expansion underscores Cerevel's commitment to advancing novel therapies for neurological disorders.
With key data readouts expected in 2024 and a clear roadmap for regulatory filings, Cerevel is poised for significant growth and impact in the neurology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in cash is fair to Cerevel shareholders. Halper Sadeh encourages Cerevel shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Ce.

CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders

AbbVie

Amgen

AstraZeneca

Bristol-Myers

Horizon Pharma

ImmunoGen

Karuna Therapeutics Inc

Mirati Therapeutics

Pfizer

Roche Holding AG

RayzeBio Inc

Seagen

CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.

Cramer names biopharma companies to watch as industry mergers start to pile up

From a technical perspective, Cerevel Therapeutics Holdings, Inc. (CERE) is looking like an interesting pick, as it just reached a key level of support. CERE's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Therapeutics (NasdaqCM: CERE) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Cerevel will receive $45.00 in cash for each share of Cerevel that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.

CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.

AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio

AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks, analysts said.

AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say

Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to be on a buying spree AbbVie is willing to spend about $8.

Cramer reacts to AbbVie buying Cerevel Therapeutics

AbbVie Inc announced late Wednesday an agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $45 per share in cash, or a total equity value of approximately $8.7 billion.  Cerevel's portfolio includes drugs such as Emraclidine, an experimental treatment for both schizophrenia and Alzheimer's disease psychosis, which is currently in a Phase I study in elderly healthy volunteers.

AbbVie to acquire drugmaker Cerevel Therapeutics for $8.7B

U.S. drugmaker Abbvie said on Thursday it does not expect any transactions similar to its $8.7 billion buyout of Cerevel Therapeutics in the foreseeable future and would instead focus on smaller deals to support its growth.

Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

Cerevel Therapeutics (NASDAQ: CERE ) stock is on the rise Thursday after the clinical-stage biopharmaceutical company reached an acquisition deal with AbbVie (NYSE: ABBV ). That deal has AbbVie agreeing to acquire Cerevel Therapeutics for $8.7 billion.

Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVie's neuroscience pipeline.

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

MILWAUKEE , Dec. 6, 2023 /PRNewswire/ -- Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie. Click here to learn how to join the https://www.ademilaw.com/case/cerevel-therapeutics or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Cerevel Therapeutics has obtained a Fair Price in its transaction with AbbVie

NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already identified potential conflicts of interest related to the merger. For a free consultation and to learn about our investigation, click here or visit: https://julieholleman.com/?p=3218 On December 6, 2023, Cerevel announced that it had entered into an agreement for the company to be acquired by AbbVie for $45 per share, or a total of $8.7 billion.

CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics

Trading in the options of Cerevel Therapeutics Holdings Inc experienced an unusual surge along with its stock price in the days before Wednesday's announcement that AbbVie would buy the drug developer in a multi-billion dollar deal.

Cerevel options trading surge before AbbVie deal news raises eyebrows

AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its huge-selling arthritis drug Humira faces a raft of new competition.

AbbVie to buy drug developer Cerevel for $8.7 billion

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel's “robust” neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remain Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion AbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CT NORTH CHICAGO, Ill.

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc , a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.

Exclusive: AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources

Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease

Cerevel Therapeutics to Host Investor Webcast on Tavapadon in Parkinson's Disease

Revolution Medicines

Vericel

InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA: XBI ).

3 Biotech Stocks That Could Boom or Bust by 2025

CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the month of November. President and chief executive officer Ron Renaud will also participate in fireside chats at both conferences.

Cerevel Therapeutics to Present at Upcoming Investor Conferences

The mean of analysts' price targets for Cerevel Therapeutics Holdings, Inc. (CERE) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Cerevel Therapeutics Holdings, Inc. (CERE) Could Surge 27.31%: Read This Before Placing a Bet

Cerevel Therapeutics Holdings, Inc. (CERE) Q3 2023 Earnings Call Transcript

Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass.

News for Cerevel Therapeutics Holdings Inc Stock (CERE)